OBJECTIVE: We tested whether two single-nucleotide polymorphisms (SNPs) (rs2383207 and rs10757278), previously strongly associated with myocardial infarction, are independently associated with stroke and coronary events in patients with hypertension. METHODS: The Nordic Diltiazem study compared the effects of calcium antagonist and beta-blocker or diuretic-based antihypertensive treatment on cardiovascular events in 10 881 patients with hypertension, of whom 5262 patients provided DNA for the present study. We related SNPs rs2383207 and rs10757278 to stroke and to myocardial infarction and coronary revascularizations (coronary events) using crude and multivariate adjusted Cox proportional hazards models. RESULTS: The G-allele of both SNPs predicted coronary events in crude recessive models [hazard ratios = 1.36, 95% confidence interval (CI) = 1.04-1.79, P = 0.02 for rs10757278 and hazard ratios = 1.40, 95% CI = 1.08-1.81, P = 0.01 for rs2383207] as well as after adjustment for classical cardiovascular risk factors. The G-allele of both SNPs predicted incident stroke in crude additive models [rs2383207 hazard ratios = 1.25 (95% CI = 1.02-1.53), P = 0.04 and rs10757278 hazard ratios = 1.34 (95% CI = 1.09-1.65), P = 0.006], as well as after adjustment for classical cardiovascular risk factors and after additional adjustment for prevalent and incident coronary events, atrial fibrillation, ischemic heart disease and congestive heart failure. As was the case for coronary events, the excess genetic risk of stroke was driven by subjects homozygous for the risk allele. CONCLUSION: Genetic variation at the CDKN2A/CDKN2B locus predicts stroke in hypertensive patients. The genetic association with stroke is independent of classical cardiovascular risk factors and of all prevalent and incident coronary events, suggesting that gene variation at this locus promotes either atherosclerosis or another disease mechanism that is common to both coronary and cerebrovascular disease.
OBJECTIVE: We tested whether two single-nucleotide polymorphisms (SNPs) (rs2383207 and rs10757278), previously strongly associated with myocardial infarction, are independently associated with stroke and coronary events in patients with hypertension. METHODS: The Nordic Diltiazem study compared the effects of calcium antagonist and beta-blocker or diuretic-based antihypertensive treatment on cardiovascular events in 10 881 patients with hypertension, of whom 5262 patients provided DNA for the present study. We related SNPs rs2383207 and rs10757278 to stroke and to myocardial infarction and coronary revascularizations (coronary events) using crude and multivariate adjusted Cox proportional hazards models. RESULTS: The G-allele of both SNPs predicted coronary events in crude recessive models [hazard ratios = 1.36, 95% confidence interval (CI) = 1.04-1.79, P = 0.02 for rs10757278 and hazard ratios = 1.40, 95% CI = 1.08-1.81, P = 0.01 for rs2383207] as well as after adjustment for classical cardiovascular risk factors. The G-allele of both SNPs predicted incident stroke in crude additive models [rs2383207 hazard ratios = 1.25 (95% CI = 1.02-1.53), P = 0.04 and rs10757278 hazard ratios = 1.34 (95% CI = 1.09-1.65), P = 0.006], as well as after adjustment for classical cardiovascular risk factors and after additional adjustment for prevalent and incident coronary events, atrial fibrillation, ischemic heart disease and congestive heart failure. As was the case for coronary events, the excess genetic risk of stroke was driven by subjects homozygous for the risk allele. CONCLUSION: Genetic variation at the CDKN2A/CDKN2B locus predicts stroke in hypertensivepatients. The genetic association with stroke is independent of classical cardiovascular risk factors and of all prevalent and incident coronary events, suggesting that gene variation at this locus promotes either atherosclerosis or another disease mechanism that is common to both coronary and cerebrovascular disease.
Authors: Phillip E Melton; Sue Rutherford; Venkata Saroja Voruganti; Harald H H Göring; Sandra Laston; Karin Haack; Anthony G Comuzzie; Thomas D Dyer; Matthew P Johnson; Jack W Kent; Joanne E Curran; Eric K Moses; John Blangero; Ana Barac; Elisa T Lee; Lyle G Best; Richard R Fabsitz; Richard B Devereux; Peter M Okin; Jonathan N Bella; Uli Broeckel; Barbara V Howard; Jean W MacCluer; Shelley A Cole; Laura Almasy Journal: Hum Mol Genet Date: 2010-07-03 Impact factor: 6.150
Authors: Christopher D Anderson; Alessandro Biffi; Natalia S Rost; Lynelle Cortellini; Karen L Furie; Jonathan Rosand Journal: Stroke Date: 2010-04-15 Impact factor: 7.914
Authors: Yan Gong; Amber L Beitelshees; Rhonda M Cooper-DeHoff; Maximilian T Lobmeyer; Taimour Y Langaee; Jun Wu; Sharon Cresci; Michael A Province; John A Spertus; Carl J Pepine; Julie A Johnson Journal: Circ Cardiovasc Genet Date: 2011-03-03
Authors: Marek Kiliszek; Anna Szpakowicz; Maria Franaszczyk; Witold Pepinski; Ewa Waszkiewicz; Malgorzata Skawronska; Rafal Ploski; Anna Niemcunowicz-Janica; Monika Budnik; Dominika Poludniewska; Wlodzimierz Jerzy Musial; Karol Adam Kaminski; Grzegorz Opolski Journal: Heart Vessels Date: 2015-11-28 Impact factor: 2.037
Authors: Natalia V Rivera; Robert Carreras-Torres; Roberta Roncarati; Chiara Viviani-Anselmi; Francesca De Micco; Alessandra Mezzelani; Werner Koch; Petra Hoppmann; Adnan Kastrati; Alexandre F R Stewart; Li Chen; Robert Roberts; Lennart C Karssen; Najaf Amin; Valentina Trimarco; Raffaele Izzo; Guido Iaccarino; Gerolama Condorelli; Annibale A Puca; Paolo Pagnotta; Flavio Airoldi; Bruno Trimarco; Cornelia M van Duijn; Gianluigi Condorelli; Carlo Briguori Journal: BMC Med Genet Date: 2013-01-23 Impact factor: 2.103
Authors: Øyvind Helgeland; Jens K Hertel; Anders Molven; Helge Ræder; Carl G P Platou; Kristian Midthjell; Kristian Hveem; Ottar Nygård; Pål R Njølstad; Stefan Johansson Journal: Int J Endocrinol Date: 2015-05-18 Impact factor: 3.257
Authors: Riyaz S Patel; Folkert W Asselbergs; Arshed A Quyyumi; Tom M Palmer; Chris I Finan; Vinicius Tragante; John Deanfield; Harry Hemingway; Aroon D Hingorani; Michael V Holmes Journal: J Am Coll Cardiol Date: 2014-03-07 Impact factor: 24.094